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Abstract
Aims: This study investigated patterns and trajectories of substance use, with a special focus on
illicit drugs other than cannabis. It examined both patterns and trajectories of use among a
general population-based sample. Methods: We used data from the 2011 French ESCAPAD
survey of French 17-year-olds to assess exposure and age of initiation of 14 licit and illicit
drugs (N=23,882). Latent class analysis (LCA) and survival analyses were performed. Results: The
results of the LCA showed that patterns of illicit drug use clearly distinguished between two
groups of other illicit drugs: 1) amphetamines/speed, cocaine, ecstasy/MDMA, magic mush-
rooms, poppers, and solvents; 2) crack/freebase, GHB/GBL, heroine, LSD, and ketamine.
Survival analyses highlighted that trajectories involved the first group before the second
one. Conclusions: Prototypical drug use patterns and trajectories should include a distinction
between two groups of illicit drugs. Preventive actions should focus on young people in their
early teens, since very young users are more likely to progress to illicit drug use, and further
studies should include this distinction instead of aggregating other illicit drugs into a single
category.
Keywords
General population-based sample, patterns
of drug use, stages of drug use
History
Received 17 March 2015
Revised 13 May 2015
Accepted 11 June 2015
Published online 20 January 2016
Introduction
Drug use among young people is a major public health con-
cern since it is associated with several detrimental conse-
quences. It is important, therefore, to understand how young
people use drugs in order to help substance use prevention.
The first stages of involvement in drug use are well known
(Kandel, 1975; Kandel et al., 2006). As described in several
countries, young people commonly start with alcohol, move
on to tobacco, then use cannabis, and finally use other illicit
drugs (Fergusson et al., 2006; Kandel, 2002; Pentz & Li,
2002; Wagner & Anthony, 2002; Willner, 2001; Woodcock
et al., 2015; Yamaguchi & Kandel, 1984).
Trajectories of the illicit use of drugs other than cannabis
have only been investigated to a lesser extent in previous
studies. Indeed, the use of several other illicit drugs may
vary according to the context (e.g. availability, price, trends),
and therefore the order in which other illicit drugs are used
after cannabis is not uniform across different societies (Hays
et al., 1986; Windle et al., 1989). Previous studies on drug use
trajectories often aggregated illicit drugs other than cannabis
into a single group (Kandel & Yamaguchi, 2002).
Unfortunately, studies examining the relevance of aggregating
all illicit drugs other than cannabis into a single category are
scarce. A recent study examined this issue, including a wide
range of illicit drugs other than cannabis, and identified two
categories of other illicit drugs instead of one: “middle-stage”
drugs (i.e. uppers, hallucinogens, and inhaled drugs) and
“final-stage” drugs (i.e. heroin, ketamine, GHB/GBL,
research chemicals, crystal meth, and spice) (Baggio et al.,
2014). However, that study among young Swiss men in their
twenties was unable to show any progression within the
sequence of drug use. That study thus highlighted stable
patterns of drug use in young adulthood, but not trajectories.
Thus, the present study’s aims were threefold. By focusing
on drug use patterns, the first aim was to test whether there
was a difference between middle- and final-stage drugs in a
sample of French teenagers. The second aim was to examine
trajectories of drug use. We hypothesized that chronological
trajectories would follow a typical progression of first alco-
hol, second tobacco, third cannabis, fourth middle-stage
drugs, and fifth final-stage drugs. Finally, by focusing on
subgroups of heavy drug users, the third aim was to test
whether the prototypical trajectory identified for the general
population also fitted these atypical young people.
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The data for this study come from the seventh ESCAPAD
survey (Survey on Health and Behaviour), a cross-sectional
survey designed to estimate drug use prevalence in France
and carried out regularly by the French Monitoring Centre for
Drugs and Drug Addiction in association with the National
Service department. It took place during the national defense
preparation day, a ‘one-day session of civic and military
information’ compulsory for all French 17 years old adoles-
cents. ESCAPAD data collection took place in March 2011 in
all the civilian or military centres across the national territory
and overseas. The survey has obtained the Public Statistics
general interest seal of approval from the National Council for
Statistical Information, the approval of the ethics commission
of the National Data Protection Authority (CNIL), and the
questionnaire follows the recommendations of the European
Monitoring Centre for Drug and Drug Addiction. A complete
description of the methodology has been published elsewhere
(Beck et al., 2006; see also Spilka et al., 2012).
In 2011, 32 249 French adolescents were surveyed.
Missing values (gender, age missing, and with more than
half the variables missing) were list wise deleted. The
response rate exceeded 98% for socio-demographic and drug
use questions. The final sample comprised 25 527 French
teenagers aged 17 living in France metropolitan. This study




Lifetime use of alcohol, tobacco, cannabis, magic mush-
rooms, poppers, solvents, ecstasy/MDMA, amphetamines/
speed, LSD, crack/freebase, cocaine, heroin, ketamine, and
GHB/GBL was assessed. Ages at which initiation to each
substance occurred were also recorded. Latent class analysis
was used to identify groups of drug users (see below).
Atypical/heavy drug users
Three subgroups of drug users were used to assess heavy drug
use and atypical drug use: (1) alcohol users subject to
repeated drunkenness (ten times or more within the previous
year, n= 2888); (2) cannabis dependent users (assessed using
the cannabis abuse screening test, CAST, Legleye et al., 2007,
2011, n= 1485); and (3) injecting drug users (n= 98).
Statistical analyses
The first statistical analyses carried out were descriptive
statistics for substance use. Next, latent class analysis (LCA)
was performed to derive groups of individuals sharing com-
mon patterns of substance use. The parameters’ estimation
was performed with Maximum Likelihood estimation with
robust standard errors (MLR) with a logit link. Models with
different numbers of latent classes were compared in order to
assess the optimal number of classes, using the Bayesian
information criterion (BIC), sample-size adjusted BIC
(ABIC), and Akaike information criterion (AIC). Lower
values indicated a better fit (Raftery, 1995). The Lo–
Mendel–Rubin likelihood ratio test (LMR LRT) indicated
whether a model with k classes is better than a model with
k-1 classes (Lo et al., 2001), and a significant p value indi-
cated that the model with k − 1 classes has been rejected in
favor of the model with k classes.
The following step involved survival analyses to study
trajectories of drug use. Seventeen-year-old participants may
not have had the time to progress in the drug course yet, and it
was unknown whether these participants will initiate it later.
Survival analyses were set up to analyze these kinds of
censored data (Lee & Wang, 2008; Singer & Willett, 2003).
The Kaplan–Meier estimator was used to estimate the survi-
val function for the groups identified by the LCA. Groups of
users were created according to the classes identified by the
LCA. Different Kaplan–Meier survival curves were drawn for
each group of drug users, and the mean survival time for each
group was calculated (i.e. their mean age of first drug use).
For groups referring to several drugs, the earliest age of onset
was reported. Significant differences between survival curves
were assessed using the Breslow test. Five survival analyses
were performed, one for each group of drugs. We also per-
formed comparisons of the ages of initiation between the five
groups of drugs. For each group of drug users, we computed
adjacent paired t-tests.
Finally, mean ages at first use and paired t-tests for age at
initiation were computed for the three subgroups of atypical/
heavy drug users (regular drunkenness, cannabis dependent
users, injecting drug users) to see whether their trajectories
fitted those of the general sample. Analyses were carried out
using Mplus version 6 (LCA) and SPSS version 21 (descrip-
tive statistics and survival analyses).
Results
The mean age of the participants was 17.38 ± 0.26 years. The
sample contained 50.3% of girls. Descriptive statistics for
substance use are provided in Table 1. Most participants had
initiated alcohol (91.2%) and tobacco (68.1%) use. A total of
Table 1. Descriptive statistics for substance use.
Lifetime use
(%, n)
Age of initiation among users
(mean, SD)
Alcohol 91.2 (23,270) 13.77 (2.25)
Tobacco 68.1 (17,380) 14.12 (1.78)
Cannabis 41.2 (10,526) 15.36 (1.21)
Solvents 5.4 (1,368) 14.95 (1.12)
Crack/freebase 0.7 (186) 15.58 (1.89)
GHB/GBL 0.5 (120) 15.52 (2.35)
Heroin 0.7 (188) 15.64 (1.95)
Ketamine 0.5 (117) 15.73 (2.39)
Poppers 8.6 (2,184) 15.99 (1.12)
Magic
mushrooms
3.2 (825) 15.99 (1.47)
Ecstasy/MDMA 1.7 (429) 16.03 (1.46)
Cocaine 2.8 (703) 16.04 (1.34)
Amphetamines/
speed
2.1 (536) 16.05 (1.33)
LSD 1.2 (302) 16.14 (1.44)






























41.2% had used cannabis. The other most prevalent illicit
drugs used were poppers (8.6%), solvents (5.4%), magic
mushrooms (3.2%), and cocaine (2.8%).
Pattern of drug use: LCA
The optimal number of classes was assessed by running
analyses from a one-class model to a seven-class model
(Table 2). AIC, BIC, and ABIC kept decreasing as the num-
ber of classes increased, except for BIC, which increased
between the six- and seven-class models. However, the gen-
erally consistent decrease was very low for the six- and seven-
class models in comparison to the five-class model. The LMR
LRT displayed highly significant p values until the compar-
ison of the five- and six-class models, for which the p value
was 0.030. Since a large sample size can handle the extraction
of additional latent classes, we selected the five-class model;
it displayed a highly significant difference from the four-class
model, but only small differences in all the fit indices when
using the six-class model.
Table 3 shows the results of the five-class model selected,
corresponding to the five different patterns of drug use.
The first latent class group was labeled “alcohol users”,
since it included participants with a high probability of alco-
hol use (1.00), and low probabilities of other substance use
(≤0.008). The second latent class group was labeled ‘alcohol
and tobacco users’ because participants in this class displayed
high probabilities of alcohol (0.936) and tobacco (0.958) use.
Other substance use probabilities were lower (0.250 for can-
nabis use; ≤0.019 for other illicit drug use).
The third latent class group was labeled “alcohol, tobacco,
and cannabis users”, with high probabilities of use for these
three substances (0.998, 0.984, and 0.937, respectively) and
low probabilities for other illicit drug use (0.187 for poppers;
.101 for solvents; ≤0.043 for other illicit drug use).
The fourth latent class group was labeled “alcohol,
tobacco, cannabis, and middle-stage drug users”, with parti-
cipants having significant probabilities of using many drugs
(0.992 for alcohol; 0.987 for tobacco; 0.980 for cannabis, and
from 0.311 to 0.473 for middle-stage drugs, namely amphe-
tamines/speed, cocaine, ecstasy, LSD, poppers, and solvents),
but low probabilities of using others illicit drugs (0.190 for
LSD; ≤0.098 for other final-stage drugs).
Finally, the fifth latent class group was labeled “all-drug
users”, including high probabilities for the use of all drugs,
including both middle-stage drugs (from 0.698 to 0.970) and
final-stage drugs (from 0.551 to 0.952 for crack/freebase,
GHB/GBL, heroine, LSD, and ketamine). The most preva-
lent group was the third latent class of “alcohol, tobacco
users and cannabis users” (39.54%). The least prevalent
group was “all-drug users” (latent class 5) with 0.03% of
participants.
Trajectories of drug use: Survival analyses
The mean ages at which participants had initiated each class
of substance was calculated using the survival curves, and
they are reported in Table 4.
For alcohol use (column 1, Table 4), the difference
between the mean ages of alcohol initiation was non-signifi-
cant for whether participants had experienced tobacco or not
(14.05 and 14.16, respectively, p= 0.271). Conversely, can-
nabis users had experienced alcohol earlier (13.61) than alco-
hol and tobacco users (p< 0.001). The result was the same for
middle-stage drug users; they had initiated alcohol before the
Table 2. Comparisons of different latent class analysis models.
Model AIC BIC ABIC LRM p value
One-class 125 093.72 125 206.86 125 162.37 –
Two-class 110 288.15 110 522.90 110 430.34 <0.001
Three-class 104 515.98 105 271.54 105 131.71 <0.001
Four-class 104 102.93 104 579.71 104 392.21 <0.001
Five-class 103 561.58 104 159.56 103 924.39 <0.001
Six-class 103 414.38 104 133.58 103 850.74 0.597
Seven-class 103 283.07 104 123.48 103 792.97 0.183
Table 3. Five-class model of substance use.
Latent classes
1-class 2-class 3-class 4-class 5-class
Probability of substance use
Alcohol 1.00 0.936 0.998 0.992 1.00
Tobacco 0.000 0.958 0.984 0.987 0.941
Cannabis 0.008 0.250 0.937 0.980 0.848
Poppers 0.002 0.019 0.187 0.473 0.790
Magic mushrooms 0.000 0.002 0.043 0.417 0.764
Cocaine 0.000 0.000 0.030 0.399 0.970
Solvents 0.000 0.016 0.101 0.347 0.698
Amphetamine/speed 0.009 0.002 0.015 0.329 0.907
Ecstasy 0.001 0.000 0.006 0.311 0.925
LSD 0.000 0.000 0.005 0.190 0.952
Heroin 0.000 0.000 0.004 0.098 0.766
Ketamine 0.000 0.000 0.000 0.055 0.754
Crack/freebase 0.000 0.000 0.009 0.071 0.593
GHB/GBL 0.000 0.000 0.005 0.039 0.551
Percentage of latent class membership (n) 26.02 (6,231) 30.85 (7,368) 39.54 (9,442) 3.26 (778) 0.03 (81)
High probabilities are highlighted in bold.






























three aforementioned groups (13.09, p< 0.001). There was no
difference between middle-stage drug users and all-drug users
in the initiation of alcohol (p= 0.124).
For tobacco use (column 2, Table 4), the group of alcohol
users was excluded from the analysis because these partici-
pants had never used tobacco. There was a significant differ-
ence between each group of drug users. For example, all-drug
users experienced tobacco before middle-stage drug users (at
13.12 and 13.57, respectively, p< 0.001).
A similar pattern was found for cannabis users (column 3,
Table 4); cannabis users had initiated cannabis later than
middle- and final-stage drugs users (15.54, p< 0.001), and
middle-stage drug users had first experienced cannabis later
than all-drug users (15.03 and 14.78, respectively, p= 0.013).
Finally, all-drug users had first experienced middle-stage
drugs earlier than middle-stage drug users (15.15 and 15.66,
respectively, p< 0.001; see column 4, Table 4). All-drug
users had, on average, first experienced final-stage drugs at
15.81 (column 5, Table 4).
Paired t-tests showed that for each group of drug users, the
initiation to earlier stage substances occurred a significant time
earlier (e.g. middle-stage drug users were first initiated to alco-
hol, then tobacco, then cannabis, and finally middle-stage drugs,
p< 0.001 for all comparisons). The only non-significant differ-
ence was all-drug users first initiations to alcohol and tobaccos.
Trajectories among heavy/atypical drug users
Table 5 summarizes the results for the three subgroups of
heavy/atypical drug users. For all of them, trajectories first
included alcohol and tobacco (no significant differences for
dependent cannabis users and injecting drug users), then
cannabis (p< 0.001), afterwards middle-stage drugs (p<
0.001), and lastly final-stage drugs (p< 0.001).
Discussion
This study’s first aim was to test whether there was a differ-
ence between “middle-stage” and “final-stage” drugs by
examining substance use patterns among a representative
sample of French 17-year-old young people.
The results showed that their patterns of drug use included
five different patterns of drug use: alcohol users only; alcohol
and tobacco users; alcohol, tobacco, and cannabis users; alcohol,
tobacco, cannabis, and middle-stage drugs users; and all-drug
users (including alcohol, tobacco, cannabis, middle-stage drugs,
and final-stage drugs). Middle-stage drugs included ampheta-
mines/speed, cocaine, ecstasy/MDMA, magic mushrooms, pop-
pers, and solvents. Final-stage drugs included crack/freebase,
GHB/GBL, heroin, LSD, and ketamine. Most of these sub-
stances corresponded to the previous classification of middle-
stage and final-stage drugs developed by Baggio et al. (2014)
(middle-stage drugs being hallucinogens/magic mushrooms,
ecstasy, cocaine, poppers, solvents, speed, salvia divinorum,
other hallucinogens, and amphetamines/methamphetamines;
final-stage drugs being crystal meth, heroin, ketamine,
GHB/GBL, research chemicals, and spice). Even though the
drugs investigated in France were not exactly the same as
those investigated in Switzerland, the results seemed robust,
Table 5. Mean ages of substance initiation for three subgroups of heavy drug users.
Substances






12.90 (n= 2751) 13.46*** (n= 2705) 14.90*** (n= 2323) 15.57*** (n= 1184) 15.83*** (n= 132)
Cannabis dependent
users n= 1485
12.94 (n= 1368) 12.89 (n= 1457) 14.39*** (n= 1432) 15.41*** (n= 810) 15.76*** (n= 140)
Injecting drug users
n= 98
12.20 (n= 82) 12.23 (n= 83) 13.67*** (n= 67) 14.64*** (n= 63) 15.40*** (n= 43)
***Indicates a significant difference (p< 0.001) between initiation ages for each subgroup of heavy drug users (paired t-tests, comparisons between
adjacent means), comparisons along lines.
Table 4. Mean ages of substance initiation for different groups of users (Kaplan–Meier estimator).
Substances
Alcohol Tobacco Cannabis Middle-stage drugs Final-stage drugs
Group of drug users Alcohol (n= 6,084) 14.05a – – – –
Tobacco (n= 6,6775) 14.16a 14.56a *** (2) – – –
Cannabis (n= 7,050) 13.61b (1) 14.04b *** 15.54a *** – –
Middle-stage drugs (n= 3,641) 13.09c 13.57c *** 15.03b *** 15.66a *** –
All drugs (n= 432) 12.89c 13.12d 14.78c *** 15.15b *** 15.81***
One column = one survival analysis (Kaplan–Meier estimator).
a,b,c,d Different letters indicate significant differences (p< 0.05) between the survival curves for each substance (Breslow test), comparisons in columns.
Example (1): cannabis users experienced alcohol before tobacco and alcohol user group members, but after middle-stage and all-drugs user group
members.
*** Indicates a significant difference (p< 0.001) between initiation ages for each group of drug users (paired t-tests, comparisons between adjacent
means), comparisons along lines. Example (2): tobacco users experienced tobacco significantly later than alcohol.






























strongly supporting the existence of two different classes of
illicit drug use.
The second aim was to examine the trajectories of drug
use. The hypothesis of a chronological trajectory following a
typical progression of first alcohol, second tobacco, third
cannabis, fourth middle-stage drugs, and fifth final-stage
drugs, was supported. Indeed, the results of the survival
analyses showed that the patterns of drug use identified in
the first part of the analyses followed a chronological order of
initiation. Therefore, the present study’s results replicated
some well-known findings, above all that trajectories begin
with alcohol, then move to tobacco, then cannabis, and finally
other illicit drugs (Fergusson et al., 2006; Kandel, 1975,
2002; Pentz & Li, 2002; Wagner & Anthony, 2002; Willner,
2001; Woodcock et al., 2015; Yamaguchi & Kandel, 1984).
Moreover, they highlighted a difference in the age of initia-
tion between middle-stage and final-stage drug users. Indeed,
users of final-stage drugs had initiated all the other substances
at a younger age than the other groups of drug users (except
for alcohol, initiated at the same age by middle-stage and
final-stage drug users). The middle-stage drug users group
displayed the second youngest age of initiation for other
substances (alcohol, tobacco, cannabis, and middle-stage
drugs). Clearly, therefore, illicit drug users (other than canna-
bis users) started to use other substances earlier than those
who had not progressed to them. This result was important
because it underlines the need to prevent substance use initia-
tion at an early age.
An additional aim was to test whether this prototypical
trajectory highlighted among a general population-based sam-
ple also fitted young people who had heavy/atypical sub-
stance use, such as repeated drunkenness, cannabis
dependence, or injecting drug use. The results showed that
the trajectory previously described also fitted those of young
people with heavy/atypical substance use. Young heavy drug
users also started with alcohol, then moved to tobacco, after-
wards to cannabis, then to middle-stage drugs, and finally to
final-stage drugs. The main difference was that their ages of
initiation occurred very early: from 12 years old for alcohol
use to 15 years old for final-stage drug use.
Overall, these results provided information about metho-
dological choices regarding classification of illicit drugs
other than cannabis. Other illicit drug use can be separated
into two categories related to different patterns and trajec-
tories of drug use. In past practices, these illicit drugs have
often been aggregated into a single category (Kandel &
Yamaguchi, 2002). The results of this study actually justi-
fied this method to some extent, since aggregating illicit
drugs into two separate classes appeared as relevant. For
example, there were some important differences between
middle- and final-stage drugs. Indeed, young people who
had moved on to middle- and final-stage drug use initiated
the first substances in their trajectories very early: around
13–15 years old for middle-stage drug users, and 12–14
years old for final-stage drug users. It is obvious that illicit
drug use does not begin with the spontaneous use of all
drugs, and that progression and intensification occur. The
use of two separate classes instead of a single class is a step
further to take this phenomenon into account, and more
studies are needed to investigate drug use patterns and
trajectories among other sample of participants and a large
extent of illicit drugs.
This study’s main limitation is that its participants were
only 17-year-olds. They may simply have been at the
beginning of their drug use trajectories, and therefore had
not yet initiated some drugs, especially middle- and final-
stage drugs. Further studies with older French young peo-
ple may include more final-stage drug users. A second
limitation was that the study focused on initiation; it did
not take into account whether young people were light or
heavy drug users. Progression along the drug use trajectory
often depends upon frequent or heavy drug use, and more
investigations are needed in order to properly consider this
variable. A last shortcoming was that the sample was a
population-based sample, and therefore that most of the
French teenagers will probably never initiate other illicit
drugs. Studies on sample of heavy drug users are needed to
investigate patterns and trajectories of illicit drug use.
Conclusion
To conclude, this study showed that prototypical drug use
patterns and trajectories should include a distinction between
two groups of illicit drugs (other than cannabis), namely
middle-stage drugs and final-stage drugs, experienced later
in the drug course. This finding replicated those of a previous
study among another large sample of older young people in
Switzerland, and therefore showed that this distinction was
robust, even if the order of other illicit drugs had been
described previously as varying across different countries.
The results were also robust for atypical young people who
were heavy substance users. Preventive actions should focus
on young people in their early teens, since very young initia-
tors are more likely to progress to middle- and final-stage drug
use, and further studies should include this distinction instead
of aggregating other illicit drugs into a single category.
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